| Literature DB >> 27616275 |
Jian Du1, Jiyan Leng1, Li Zhang1, Guangxin Bai2, Di Yang2, Huan Lin2, Junjie Qin1.
Abstract
BACKGROUND This study aimed to investigate the inhibitory effect of blueberry anthocyanin (BBA) on Angiotensin II (Ang II)-induced apoptosis of human umbilical vein endothelial cells (HUVECs), and its regulation mechanisms involving Bax and Caspase 3. MATERIAL AND METHODS HUVECs were first treated by different concentrations of Ang II (10-9, 10-8, 10-7, 10-6, 10-5, and 10-4 mol/L) and BBA (80, 40, 20, 10, 5, and 2.5 μg/ml). After 24 h and 48 h of treatment, MTT was performed to detect the viability of HUVECs. Then, HUVECs were randomly divided into the Ang II group (10-6 mol/L Ang II) and Ang II + BBA group (10-6 mol/L Ang II and 20 μg/ml BBA), and the apoptosis rate was detected by flow cytometry. Western blot analysis was performed to detect the expression of Bax and Caspase 3 in these 2 groups. During the whole process, HUVECs without any treatments served as the control group. RESULTS The cell viability of HUVECs was significantly reduced by Ang II in a time- and concentration-dependent manner (P<0.05), while BBA significantly elevated the cell viability of HUVECs until a peak of 20.0 μg/ml. The apoptosis rate of HUVECs was significantly increased by Ang II (P<0.01) and reduced by the BBA intervention (P<0.05). Ang II significantly elevated the expression of Bax and Caspase 3 in HUVECs, but their expression was significantly inhibited by BBA. CONCLUSIONS BBA increased cell viability and reduced apoptosis rate of HUVECs induced by Ang II through Bax- and Caspase 3-dependent pathways.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27616275 PMCID: PMC5029175 DOI: 10.12659/msm.896916
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Cell viability of human umbilical vein endothelial cells (HUVECs) treated by different concentrations of Ang II and blueberry anthocyanin (BBA) (n=5).
| Concentrations of Ang II | Cell viability (OD/%) | Concentrations of BBA | Cell viability (OD/%) | ||
|---|---|---|---|---|---|
| 24 h | 48 h | 24 h | 48 h | ||
| 0 mol/L | 1.11±0.03 (100%) | 1.09±0.01 (100%) | 0 μg/ml | 1.15±0.02 (100%) | 1.18±0.02 (100%) |
| 10−9 mol/L | 0. 98±0.02 (90%) | 0.98±0.01 (89%) | 2.5 μg/ml | 1.23±0.04 (107%) | 1.23±0.04 (104%) |
| 10−8 mol/L | 0.93±0.01 (84%) | 0.89±0.02 (81%) | 5.0 μg/ml | 1.25±0.04 (109%) | 1.26±0.03 (106%) |
| 10−7 mol/L | 0.84±0.02 (76%) | 0.80±0.02 (73%) | 10.0 μg/ml | 1.27±0.01 (111%) | 1.32±0.03 (112%) |
| 10−6 mol/L | 0.80±0.01 (73%) | 0.74±0.01 (68%) | 20.0 μg/ml | 1.31±0.01 (114%) | 1.39±0.01 (117%) |
| 10−5 mol/L | 0.71±0.03 (66%) | 0.66±0.03 (60%) | 40.0 μg/ml | 1.22±0.01 (107%) | 1.19±0.04 (102%) |
| 10−4 mol/L | 0.62±0.03 (56%) | 0.55±0.03 (50%) | 80.0 μg/ml | 1.01±0.03 (89%) | 0.99±0.07 (84%) |
Represent significantly different at P<0.05 and P<0.01 when compared with HUVECs without treatment, respectively.
Represent significantly different at P<0.05 when compared with 24 h of treatment.
Figure 1Apoptosis of human umbilical vein endothelial cells (HUVECs) treated by 10−6 mol/L Ang II and 20.0 μg/ml blueberry anthocyanin (BBA). *, ** Represent significantly different at P<0.05 and P<0.01, respectively, when compared with HUVECs without treatment (Control). # Represents significantly different at P<0.05 when compared with Ang II group.
Figure 2The expression of Bax and Caspase 3 in human umbilical vein endothelial cells (HUVECs) treated by 10−6 mol/L Ang II and 20.0 μg/ml blueberry anthocyanin (BBA). GAPHD was used as internal control.